Breakthrough Parkinson’s Trial Goes Decentralized | BioVie Inc. at ATMRD Congress

Investors and biotech enthusiasts—BioVie Inc. is making waves at the ATMRD Congress with its Sunrise PD trial, a hybrid decentralized Phase 2 study targeting early-stage Parkinson’s disease. The study features home visits, telehealth, and digital assessments, reducing barriers for participants with mobility challenges.

At the heart of the trial is Bezistarum, a novel oral therapy focused on combating inflammation and insulin resistance—two critical drivers in Parkinson’s. With backing from the Michael J. Fox Foundation and promising early results, this is a pivotal trial to watch. Top-line data is expected by late 2025.

Stay updated on game-changing biotech innovations—subscribe for more.

#ParkinsonsResearch
#BiotechNews
#ClinicalTrials
#DecentralizedTrials
#Bezistarum
#BioVieInc
#SunrisePD
#ATMRDCongress
#Neuroscience
#DigitalHealth
#MichaelJFoxFoundation
#Inflammation
#InsulinResistance
#NewsOut
#BiotechInvesting
#PharmaNews

Видео Breakthrough Parkinson’s Trial Goes Decentralized | BioVie Inc. at ATMRD Congress канала NewsOut